Journal article
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
B Mak, HM Lin, EM Kwan, H Fettke, B Tran, ID Davis, K Mahon, MR Stockler, K Briscoe, G Marx, A Zhang, M Crumbaker, W Tan, K Huynh, TG Meikle, NA Mellett, AJ Hoy, P Du, J Yu, S Jia Show all
BMC Medicine | Published : 2022
Abstract
Background: Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). A key question is how the lipid environment and the cancer genome are interrelated in order to exploit this therapeutically. We assessed the association between the poor prognostic 3-lipid signature (3LS), somatic genetic aberrations and clinical outcomes in mCRPC. Methods: We performed plasma lipidomic analysis and cell-free DNA (cfDNA) sequencing on 106 men with mCRPC commencing docetaxel, cabazitaxel, abiraterone o..
View full abstractGrants
Awarded by University of Sydney
Funding Acknowledgements
National Health and Medical Research Council of Australia (GNT1196225 to LGH, GNT1098647 to AAA); Cancer Institute New South Wales (10/TPG/1-04, 2018/TPG001); Australian Prostate Cancer Research Centre-New South Wales; Australian Department of Health and Aging; the Movember Foundation and the Prostate Cancer Foundation of Australia (Revolutionary Team Award MRTA3); Cancer Council New South Wales (PG 10-01); Cancer Council South Australia (Beat Cancer Project Principal Cancer Research Fellowship, PRF1117 to LMB); The Victorian Government's Operational Infrastructure Support Program; National Institutes of Health grant award to MK (RO1-CA212097); Australian Government Research Training Program (RTP) Scholarship and University of Sydney Merit Award to BM; NHMRC Postgraduate Scholarship and Monash University Postgraduate Publications Award to EMK; Australian Government RTP Scholarship and Monash University Postgraduate Scholarship to HF; Victorian Cancer Agency Clinical Research Fellowship (CRF14009) and Astellas Investigator-Initiated Grant to AAA; ANZUP Noel Castan Fellowship to HML; Twin Towns Services Community Foundation to LGH. The funders had no roles in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.